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Most deaths from severe falciparum malaria occur within 24 hours of presentation to 53 
hospital. Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum 54 
malaria, but its efficacy may be compromised by delayed parasitological responses.  55 
In patients with severe malaria the life-saving benefit of the artemisinin derivatives is 56 
their ability to clear circulating parasites rapidly, before they can sequester and 57 
obstruct the microcirculation. To evaluate the dosing of i.v. artesunate for the 58 
treatment of artemisinin-sensitive and reduced ring stage sensitivity to artemisinin 59 
severe falciparum malaria infections Bayesian pharmacokinetic-pharmacodynamic 60 
modelling of data from 94 patients with severe malaria (80 children from Africa and 61 
14 adults from Southeast Asia) was performed. Assuming delayed parasite clearance 62 
reflects a loss of ring stage sensitivity to artemisinin derivatives, the median (95% 63 
credible interval) percentage of patients clearing ≥99% parasites within 24 hours 64 
(PC24≥99%) for standard (2.4 mg/kg i.v. artesunate at 0 and 12 hours) and simplified 65 
(4 mg/kg i.v. artesunate at 0 hours) regimens were 65% (52.5%-74.5%) versus 44% 66 
(25%-61.5%) for adults, 62% (51.5%-74.5%) versus 39% (20.5%-58.5%) for larger 67 
children (≥20 kg) and 60% (48.5%-70%) versus 36% (20%-53.5%) for smaller 68 
children (<20 kg). The upper limit of the credible intervals for all regimens was below 69 
a PC24≥99% of 80%, a threshold achieved on average in clinical studies of severe 70 
falciparum malaria infections. Rapid clearance of parasites, where there is loss of ring 71 
stage sensitivity to artemisinin, in patients with severe falciparum malaria is 72 
compromised with the currently recommended and proposed simplified i.v. artesunate 73 
dosing regimens. 74 
 75 
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Despite major advances in malaria control over the last decade, an estimated 405,000 79 
patients died from malaria in 2018 (1). The majority of these deaths are in African 80 
children under 5 years of age with Plasmodium falciparum malaria (1). Most deaths 81 
from severe falciparum malaria occur within the first 24 hours of presentation to a 82 
hospital (2). Early diagnosis and treatment with a highly effective antimalarial 83 
treatment is key to prevent severe malaria and death (3).  84 
 85 
The current global policy for the treatment of both uncomplicated and severe 86 
falciparum malaria (referred to as uncomplicated and severe malaria henceforth) relies 87 
on the artemisinin derivatives. The World Health Organisation (WHO) treatment 88 
guidelines recommend artemisinin combination therapy (ACT) for uncomplicated 89 
malaria and intravenous (i.v.) or intramuscular (i.m.) artesunate for severe malaria (3). 90 
The reliability and rapid effectiveness of these drugs is now compromised by the 91 
emergence of slow clearing parasites with decreased sensitivity to artemisinin 92 
derivatives in the Greater Mekong Subregion (4, 5). Optimising the dosing regimens 93 
for artemisinin-based therapies is crucial to extend the lifespan of these drugs and 94 
prevent the spread of parasites with decreased sensitivity to artemisinin derivatives 95 
across Asia and to Africa.  96 
 97 
Patients with severe malaria generally have a higher sequestered parasite biomass than 98 
those with uncomplicated malaria resulting from efficient multiplication at high 99 
densities (8). Decreased sensitivity to artemisinin derivatives is characterised by 100 
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delayed parasitological responses (6). The life-saving benefit of the artemisinin 101 
compounds in severe malaria results from the rapid killing and clearance of 102 
circulating parasites, before they can sequester and obstruct the microcirculation (7). 103 
There is also evidence that patients with severe malaria have higher parasite 104 
multiplication rates that contribute to the higher biomass found in severe disease, 105 
further highlighting the importance of artemisinin derivatives to clear circulating 106 
parasites rapidly (8). Hence delayed parasite clearance (reflecting reduced ring stage 107 
killing and clearance) is a major concern for the treatment of severe malaria (9).  108 
 109 
The WHO treatment guidelines for severe malaria recommend that the artemisinin 110 
derivative, artesunate, should be given at 0, 12, and 24, hours and then daily if 111 
required at a parenteral dose of 2.4 mg/kg for adults and larger children (≥20 kg) and, 112 
because of lower exposures in younger children, at a dose of  3 mg/kg for smaller 113 
children (<20 kg) (9). Once the patient can tolerate oral therapy, treatment is 114 
completed with 3 days of an ACT. In Africa, a regimen not requiring a 12 hour dose 115 
was proposed to have significant practical advantages in resource-poor settings and 116 
remote health facilities (10, 11). 117 
 118 
The parasite clearance rate is an informative pharmacodynamic variable and in silico 119 
pharmacokinetic-pharmacodynamic (PK-PD) modelling offers an informative 120 
approach to explore new dosing strategies. This approach has been used to simulate 121 
parasite clearance within the first 24 hours for patients with severe malaria. Model-122 
based findings suggest that for patients with artemisinin-sensitive infections a 123 
simplified regimen of i.m. artesunate (4 mg/kg at 0, 24 and 48 hours) is comparable in 124 
efficacy to the WHO regimen (12). Whilst the WHO recommended regimen was 125 
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predicted to be less efficacious in patients infected with parasites with decreased 126 
artemisinin sensitivity compared to sensitive parasites, the efficacy of the simplified 127 
regimen has yet to be evaluated against parasites with decreased artemisinin 128 
sensitivity. 129 
 130 
In this study, we fitted a within-host PK-PD model within a Bayesian framework to 131 
drug concentration and parasite count data from patients with severe malaria treated 132 
with two different i.v. artesunate regimens and performed an external validation. 133 
Simulations based on the joint posterior distribution of the PK-PD parameters were 134 
performed to compare the parasitological outcomes between hypothetical patients 135 
with either artemisinin-sensitive or reduced ring stage sensitivity to artemisinin severe 136 
falciparum malaria infections. 137 
 138 
RESULTS 139 
Parasitaemia (number of parasites / l of blood) profiles were available for 94 patients 140 
with severe malaria (80 children from Africa and 14 adults from Southeast Asia) 141 
treated intravenously with 2.4 mg/kg of  artesunate. Details of the trials are provided 142 
in Table 1 and published reports (10, 13). Since parasite sampling after 48 hours was 143 
sparse, parasitaemia profiles were modelled only from data collected up to and 144 
including 48 hours (Figure S1(a) and S1(b)). Baseline patient characteristics and the 145 
number of blood samples quantifying parasitaemia are summarised in Table 2.  146 
 147 
Assessment of model fit and parameter estimation 148 
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A within-host PK-PD model was incorporated into a Bayesian hierarchical model and 149 
fitted to the observed parasitaemia profiles (METHODS and Supplementary Text 1). 150 
Definitions for the nine model parameters are provided in Table 3.   151 
 152 
The posterior predictive check (Supplementary Text 2) in Figure 1(a) indicates that 153 
the within-host PK-PD model successfully captures the central trend and variability in 154 
the observed parasite count profiles.   155 
 156 
The estimates of the population average parameters are presented in Table 4. The 157 
average age of the initial parasite load (μIPL) was 12.95 hours, and the middle 50% of 158 
parasites (interquartile range) were aged between 6.16 and 18.17 hours, indicating that 159 
on admission infections consisted of parasites predominantly at the ring stage. The 160 
time delay before dihydroartemisinin (DHA) concentration levels in plasma reached 161 
the malaria parasite in red blood cells (reflected in a hypothetical intraerythrocytic 162 
effect compartment) was 3.3 hours ( log𝑒2  / 0.21). The EC50  concentration in the 163 
hypothetical compartment was 20.35 ng/ml. Assuming patients are immunologically 164 
naïve, the rate of parasite removal  resulting from processes other than the drug (δ𝑃) 165 
was 0.06 / hour, that is 6% (100 × (1 − 𝑒−0.06)) of parasites at each age will be 166 
removed every hour independent of treatment. DHA is assumed to kill parasites aged 167 
6-44 hours (referred to as DHA’s killing window). The maximal killing effect (kmax) 168 
of DHA was 0.53 / hour. Thus, for every hour that DHA concentrations are much 169 
greater than the EC50 concentration, the number of parasites within the killing window 170 
will be reduced by 41% (100 × (1 − 𝑒−0.53)).  171 
 172 
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The observed parasitaemia profiles were not informative for estimation of the 173 
population average nor individual-specific parasite multiplication factor ( PMF ). 174 
Similarly, the profiles were not informative for estimation of the slope of the in vivo 175 
concentration-effect curve (γ). For these parameters the prior and marginal posterior 176 
distributions were very similar (see Figure S2). The prior distributions for PMF and γ  177 
were based on data and parameter estimates from clinical and in vitro studies (Table 178 
S1). Figure S3 shows how the between subject variability (ω) parameters influence 179 
the shape of the marginal densities of the multivariate logistic-normal distribution 180 
specified for individual PD parameters. 181 
 182 
Parasitological outcome and dosing regimens 183 
The parasitological outcome measure selected for comparing the different i.v. 184 
artesunate regimens was clearance of 99% of a patient’s admission parasitaemia 185 
within 24 hours (PC24≥99%), a measure that has been used previously in non-186 
inferiority clinical trials of parenteral artesunate (10, 11).  The 95% credible interval 187 
for PC24≥99% simulated from the model contains the observed PC24≥99% of 82% 188 
(95% confidence interval (exact method): 70%-90%) for children and 70% (95% 189 
confidence interval: 35%-93%) for adults (Figure 1(b)). 190 
 191 
The following three dosing regimens were examined in this study:  192 
1. 2.4 mg/kg of i.v. artesunate at 0, 12, and 24, 48 and 72 hours (standard 193 
regimen).  194 
2. 4 mg/kg of i.v. artesunate at 0, 24 and 48 hours (simplified regimen).  195 
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3. 3 mg/kg of i.v. artesunate for smaller children (<20 kg) and 2.4 mg/kg for 196 
adults and larger children (>20 kg) at 0, 12, and 24, 48 and 72 hours (revised 197 
regimen).  198 
 199 
Before 2015, the “standard” regimen was recommended by the WHO. In 2012, the 200 
simplified regimen was examined in a randomised controlled trial (RCT) as an 201 
alternative to the standard regimen in resource-poor settings in Africa. In 2015, the 202 
standard regimen for children was revised based on pharmacometric modelling (14, 203 
15). The dose for smaller children was increased in the revised regimen to provide 204 
comparable drug exposure to adults and larger children. The PC24≥99%, only 205 
evaluates the efficacy of the dose(s) administered in the first 24 hours after treatment.   206 
 207 
Comparison of dosing regimens 208 
Medians (black dot) and 95% credible intervals (error bars) were used to compare the 209 
distribution of PC24≥99% derived from 100 datasets consisting of different 210 
hypothetical patient populations: 100 adults, 100 larger children and 100 smaller 211 
children (Figure 2). Simulation of hypothetical patients with either artemisinin- 212 
sensitive or reduced ring stage artemisinin sensitivity infections was performed. 213 
Decreased ring stage artemisinin sensitivity was modelled by shortening the DHA 214 
killing window from 6–44 hours to 12–44 hours to mimic a partial (i.e. 6 hour) loss of 215 
ring stage activity. The concentration-effect relationship for parasites remaining in the 216 
killing window was assumed to be the same as that inferred for artemisinin-sensitive 217 
infections.  218 
 219 
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The DHA concentration profiles for hypothetical adults, larger and smaller children 220 
given each dosing regimen are presented in Figure S4. An example of the 221 
corresponding parasitaemia profiles is presented in Figure S5.  222 
 223 
Artemisinin-Sensitive Infections 224 
The simplified 4 mg/kg i.v artesunate dose group in Kremsner et al. 2012 (10) was 225 
used for external validation of the model prediction. External validation focused on 226 
whether the model could reproduce the PC24≥99% for the simplified regimen 227 
reported in Kremsner et al. 2012 (10) – the parasitaemia profiles from the standard 228 
regimen from this study were used for model fitting.  229 
 230 
Kremsner et al. 2012 (10) reported that 78% (95% confidence interval: 69%-87%) of 231 
patients that received the simplified regimen achieved PC24≥99% and 85% (95% 232 
confidence interval: 77%-93%) of patients that received the standard regimen 233 
achieved PC24≥99%. A treatment difference of -7.2% was observed between 234 
PC24≥99% for the simplified and standard regimens. The corresponding 95% 235 
confidence interval ranged from -18.9% to 4.4% and did not include the prespecified 236 
noninferiority margin of -20%.  237 
 238 
The median (95% credible interval) for PC24≥99% for hypothetical patients with 239 
sensitive infections and administered the standard regimen were 86% (75.5%-93.5%) 240 
for adults, 83% (72.5%-90.5%) for larger children and 80% (72%-88%) for smaller 241 
children (Figure 2, top panel). These 95% credible intervals for hypothetical larger 242 
children treated with the standard regimen and for hypothetical smaller children 243 
treated with either the standard or revised regimens contain the observed percentage 244 
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and 95% confidence interval reported in Kremsner et al. 2012 (10) for the standard 245 
regimen.  246 
 247 
For the simplified regimen, the median and 95% credible interval derived from the 248 
hypothetical children (63.5% (44.5%-80%) for larger children and 58.5% (41%-74%) 249 
for smaller children) underestimated the observed PC24≥99% for the children that 250 
received the simplified regimen in Kremsner et al. 2012 
8
 (i.e. dataset for external 251 
validation, Figure 2, top panel).  252 
 253 
Decreased ring stage sensitivity to artemisinin  254 
For infections where the killing window was shortened to 12-44 hours to reduce ring 255 
stage activity, rapid clearance of such infections appears to be compromised 256 
compared to sensitive infections for both the standard (two doses of 2.4 mg/kg of i.v. 257 
artesunate at 0 and 12 hours) and simplified (single dose of 4 mg/kg at 0 hours) 258 
regimens. The median values (95% credible intervals) for standard and simplified 259 
regimens were 65% (52.5%-74.5%) versus 44% (25%-61.5%) for adults, 62% 260 
(51.5%-74.5%) versus 39% (20.5%-58.5%) for larger children (≥20 kg) and 60% 261 
(48.5%-70%) versus 36% (20%-53.5%) for younger children (<20 kg) (Figure 2, 262 
bottom panel). The upper limit of the credible intervals for all regimens was below a 263 
PC24≥99% of 80%, a threshold achieved on average in clinical studies of severe 264 
falciparum malaria infections (10, 11).  265 
 266 
DISCUSSION 267 
Our within-host PK-PD model captures the key features of malaria parasite clearance 268 
following the start of antimalarial treatment. The modelled profiles show similar 269 
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central trends (lag and decline) and variability in the observed parasitaemia profiles to 270 
those observed in African children and Southeast Asian adults who received the 2.4 271 
mg/kg i.v. artesunate dosing regimen in the studies reported by Kremsner et al. 2012 272 
(10) and Maude et al. 2009 (13), respectively (Figure 1). Simulated parasitological 273 
outcomes from the model PD parameters were able to reproduce the percentage 274 
PC24≥99% observed for the standard 5-dose (i.e. data used for model fitting). In an 275 
external validation of the simplified 3-dose i.v. artesunate regimen, based on findings 276 
reported in Kremsner et al. 2012 (10), our model underestimated the observed 277 
percentage PC24≥99%.  278 
 279 
The patient data used for our model predictions were from a setting prior to the 280 
decline in efficacy of artemisinin-based therapies being detected in Southeast Asia, 281 
consequently inferences based on posterior summaries for the PD parameters are only 282 
appropriate for infections with artemisinin sensitive parasites. In this study decreased 283 
sensitivity to artemisinin derivatives was modelled by shortening the DHA killing 284 
window, i.e. reduced ring stage activity which conforms to the in vitro observations of 285 
reduced ring stage killing. 286 
 287 
A delayed drug killing effect has been observed in in vitro (16, 17) and clinical 288 
studies for artemisinin derivatives (18, 19). The time delay before DHA plasma 289 
concentration had an apparent effect was 3.3 hours in this study, shorter than the 9 290 
hour delay estimated for Cambodian and Thai adults (18) and 5.6 hour delay 291 
estimated for adults in Southern Myanmar (19) after treatment with oral artesunate 292 
monotherapy. In addition, artemisinin induced growth retardation (20–22) and/or 293 
altering of growth patterns (23) were not modelled. 294 
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The within-host PK-PD model described in this study assumed patients were 296 
immunologically naïve. This assumption was considered reasonable as the adult 297 
patients were from Southeast Asia (a low transmission setting) and a large proportion 298 
of the African children were under 5 years (80%). Assuming the patients are 299 
immunologically naïve may cause the killing rate of the drug ( kmax ) to be 300 
overestimated, as parasite clearance is attributed to drug only and any contribution 301 
from the immune response is ignored. 302 
 303 
The model included a parameter to capture drug independent removal of parasites 304 
(δ𝑃 ) under the assumption patients were immunologically naïve (i.e. due to host-305 
specific processes, such as the finite lifespan of red blood cells) (20, 24). In this study 306 
of Southeast Asian adults and predominantly African children, drug independent 307 
removal assuming patients were immunologically naïve was inferred to be 6% of 308 
parasites every hour.  309 
 310 
The meta-analysis reported by Zaloumis et al. 2014 (14) found similar PK parameters 311 
for Southeast Asian adults and Africa children. The PK-PD analysis presented in this 312 
study assumed that the decline in parasitaemia after treatment was driven by a 313 
patient’s PK profile, and hence the PD analysis was not stratified by adult and child 314 
patients. Figure S6 illustrates that simulated profiles generated from individual PD 315 
parameters derived from the analysis of the pooled PD profiles (i.e. both adults and 316 


























Estimation of our model parameters was based on data from only 94 patients and 320 
focused on the decline in parasitaemia, and not on clinical outcomes, in the initial 24 321 
hours after treatment with intravenous artesunate. Although our model predicts a 322 
slower decline in parasitaemia for infections with decreased ring stage sensitivity to 323 
artemisinin derivatives in the first 24 hours, this may not translate to poorer clinical 324 
outcomes (25). To determine the consequences of delayed parasite clearance on 325 
clinical outcomes in severe falciparum malaria patients, studies should also focus on 326 
parasitological and clinical outcomes beyond the first 24 hours of treatment.  327 
 328 
In silico modelling of artemisinin-resistant severe malaria infections was also 329 
investigated in Jones et al. 2019 (12) by assuming early ring stage parasites were 330 
insensitive to artesunate.  The conclusions in Jones et al. 2019 (12) regarding the 331 
efficacy of the standard i.m. dosing regimen for treating resistant infections where the 332 
killing window of DHA has been reduced are consistent with ours for i.v. artesunate 333 
and suggest that the standard regimen has reduced efficacy against these infections 334 
compared to sensitive infections. Our modelling approach differs in the following 335 
ways to that adopted in Jones et al. 2019 (12): Bayesian inference was used for 336 
parameter estimation, the posterior predictive distribution was used to simulate the 337 
parasitological outcome, and the efficacy of the simplified regimen against 338 
artemisinin-resistant infections was examined. 339 
 340 
In conclusion, our study suggests that in view of the declining efficacy, including 341 
recent reports of de novo emergence of Pfkelch13-mediated delayed parasite 342 
clearance in sub Saharan Africa (26), the previous excellent therapeutic response to 343 
intravenous artesunate may be compromised in patients with severe falciparum 344 
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malaria.  In these areas, the clearance of parasites for both the standard and simplified 345 
parenteral regimens may be significantly slower. So far, in uncomplicated malaria 346 
these delayed parasite clearance phenotypes have not compromised cures with 347 
artemisinin containing combinations when the partner drug retains efficacy. 348 
Subsequently, trials focusing on both the initial parasitological response and the 349 
clinical consequences of delayed parasite clearance in severe falciparum malaria 350 
patients should be considered. New antimalarial treatments with ring stage activity are 351 
needed in the immediate future. 352 
 353 
METHODS 354 
Study population, study design, dosing and blood sampling  355 
The site, study population, design, i.v. artesunate dosing and blood sampling for the 356 
determination of DHA concentration and parasitaemia (parasites / l of blood) for 357 
both studies included in the pooled dataset are provided in Table 1.  358 
 359 
Within-host pharmacokinetic-pharmacodynamic model 360 
The within-host pharmacokinetic-pharmacodynamic (PK-PD) model was previously 361 
published in (27, 28) and describes the blood stage of a malaria infection and its 362 
response to treatment. In brief, prior to drug administration the initial parasite load 363 
(𝐼𝑃𝐿) of each patient is distributed among the 48 hourly age intervals of the P. 364 
falciparum lifecycle according to a truncated normal distribution with location 365 
parameter μ𝐼𝑃𝐿
∗  hours, scale parameter σ𝐼𝑃𝐿
∗  hours and truncation limits 1 to 48 hours 366 
(Supplementary Text 1 equation [S1]). 𝜇𝐼𝑃𝐿  and 𝜎𝐼𝑃𝐿  are the mean and standard 367 
deviation of the truncated parasite age distribution (Supplementary Text 1 equation 368 
[S2] and Figure S7). Every hour after treatment the parasites aged 1 to 47 hours are 369 
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shifted to the right and become the number of parasites aged 2 to 48 hours. The 370 
parasites aged 48 hours are then multiplied by the parasite multiplication factor (PMF, 371 
Table 3). This process was repeated for a follow-up time of 48 hours. 372 
 373 
The proportion of parasites that survive an hour of treatment with i.v. artesunate is 374 
determined by the delayed concentration-effect sigmoid-Emax model described in (18) 375 
that links the DHA concentration in the central compartment (blood plasma) to a 376 
hypothetical effect-site (intraerythrocytic) compartment (Supplementary Text 1 377 
equation [S6]). The model assumes patients are immunologically naive. The rate of 378 
parasite removal due to processes other than drug in patients assumed to be 379 
immunologically naïve, δP , is included in the model (e.g. host-specific processes, 380 
such as the lifespan of red blood cells). The PMF is corrected to account for δP 381 
(Supplementary Text 1 equation [S4]).   382 
 383 
After removal of parasites due to drug and drug independent processes, the sum of the 384 
simulated number of parasites aged 1 to 26 hours was used to predict the circulating 385 
parasitaemia at time points of interest. DHA, the active metabolite of artesunate, was 386 
assumed to kill parasites aged 6-44 hours (29). The model does not have an explicit 387 
compartment from which parasites “damaged” by drug can either be cleared or 388 
recover and returned to the blood circulation (30). Full details of the model are 389 
provided in the Supplementary Text 1.  390 
 391 
Statistical analysis 392 
The within-host model (Supplementary Text 1) was incorporated into a Bayesian 393 
hierarchical model (Supplementary Text 3) which allows the dynamics to vary across 394 
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patients and, consequently, the variation in the observed parasitaemia profiles to be 395 
modelled. Parasitaemia measurements were natural log ( loge ) transformed and 396 
assumed to follow a normal distribution where the residual standard deviation varied 397 
by observed study. Data below the microscopy limit of detection (50 parasites / l of 398 
blood) were modelled as censored data using the M3 method (31). The prior 399 
distribution for the individual-specific PD parameters was assumed to be multivariate 400 
normal (MVN) after logistic transformation (32), i.e.  401 
ϕi = loge (
θi − a
b − θi
) ∼ MVN(ϕ, Ω) 
[1] 
where ϕi and θi denote 9-dimensional vectors of individual-specific PD parameters 402 
after and before logistic transformation for the ith  individual, and a  and b  are 9-403 
dimensional vectors containing the lower and upper bounds for each PD parameter 404 
provided in Table 4 and also in Table S1 along with a justification for their selection. 405 
The mean vector (ϕ) of the MVN distribution in [1] is the logistic transform of a 9-406 
dimensional vector of population average PD parameters (θ), i.e. ϕ = log𝑒 (
θ−𝑎
𝑏−θ
). The 407 
covariance matrix (Ω) was decomposed into a vector of standard deviation parameters 408 
and a correlation matrix (see equation [S10] in Supplementary Text 3). The hyperprior 409 
distributions for the elements of the mean vector ϕ, standard deviation parameters, 410 
correlation matrix and study-specific residual error were normal(0, 1), half-normal(0, 411 
1), Cholesky LKJ correlation distribution (33, 34) with shape parameter equal to 2  412 
and half-Cauchy(0, 5), respectively. 413 
 414 
The No U-Turn (NUTS) sampler implemented in the open source software packages 415 
RStan 2.18.2 (35) and R 3.4.2 (36) was used to sample the population average PD, 416 
individual-specific PD, BSV parameter values and study-specific residual errors from 417 
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the posterior distribution. For each model parameter, four Markov chains were 418 
initialised using random numbers generated by RStan. The first 1000 parameter 419 
values sampled for each chain were discarded as burn-in and an additional 1000 420 
parameter values were sampled and combined, resulting in 4000 samples per 421 
parameter for calculation of posterior summaries. The posterior summaries calculated 422 
were the median of the 4000 samples for each parameter (posterior median) and 95% 423 
credible interval, which is calculated from the 2.5th and 97.5th percentiles of the 4000 424 
samples for each parameter. The credible interval can be interpreted as an interval in 425 
which the probability that the unknown parameter lies within is 0.95. 426 
 427 
Traceplots were examined to assess whether the 1000 parameter draws from each 428 
chain had converged to a common distribution (Figure S8). Convergence was also 429 
monitored using the ?̂? statistic, which is the ratio of the mean of the variances of the 430 
samples within each chain to the variance of the pooled samples across chains (34). If 431 
all chains have converged to a common distribution, ?̂? will be one. The effective 432 
sample size (ESS) is an estimate of the number of independent draws of the parameter 433 
of interest from the posterior distribution (34). The draws within a Markov chain are 434 
not independent and if there is high autocorrelation between the draws for a 435 
parameter, the ESS will be much smaller than the total sample size (i.e. the 4000 436 
draws retained after burn-in for each parameter). To gauge the degree to which the 437 
observed data update the prior information, a comparison of the prior distribution and 438 
marginal posterior distribution for the population average PD parameters, between-439 
subject variability and individual-specific PD parameters for an individual is provided 440 
in Figure S2. Additional details concerning model building and selection are provided 441 
in Supplementary Text 4.  442 
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Simulation of PC24≥99% under standard and simplified dosing regimens  444 
PK parameters (clearance (CL) and volume of distribution (V)) were simulated for 445 
different hypothetical patient populations (100 adults, 100 larger (≥20 kg) children 446 
and 100 smaller (<20 kg) children) from the population PK model for patients that 447 
received i.v. artesunate at baseline described in (15). Simulation of individual-specific 448 
PK parameters from this model requires age, weight, haemoglobin and body 449 
temperature values for each hypothetical patient. There was little correlation between 450 
these variables for the 14 adults in the pooled study (all Pearson’s correlations below 451 
0.4), so values of these variables for the 100 hypothetical adults were sampled from 452 
uniform distributions with limits set to the observed range for each variable: age 21-453 
62 years, weight 33-75 kg, haemoglobin 2.9-11.5 g/dl and temperature 34-39 °C.   454 
 455 
For the 80 children in the pooled study, age was correlated with both weight and 456 
haemoglobin, but temperature was not strongly correlated with any variable. Five-457 
hundred age and temperature values were sampled from uniform distributions with 458 
limits set to the observed range for the 80 children: age 0.5-9.2 years and temperature 459 
35-40 °C. The sampled age values were used to simulate 500 corresponding weight 460 
and haemoglobin values using the coefficient estimates from the linear regressions of 461 
age and weight (estimated intercept, age coefficient and residual standard error were 462 
7.02, 1.76 and 2.01, respectively), and age and haemoglobin (estimated intercept, age 463 
coefficient and residual standard error 5.79, 0.59 and 2.01, respectively) for the 80 464 
children in the study. The age, haemoglobin and temperature values for the first 100 465 
weight values ≥20 kg (<20 kg) were retained and used to simulate PK parameters for 466 
larger (smaller) children.  467 
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Then for each dosing regimen, the simulated weights and PK parameters for each 469 
hypothetical patient were used to calculate the i.v. artesunate dose in g and to 470 
simulate the DHA plasma concentration (ng/ml) from the intravenous-bolus one-471 
compartment PK model described in (15), respectively.  472 
 473 
Next, 100 datasets each consisting of 100 hypothetical adults, larger children or 474 
smaller children with parasitaemia measurements simulated at 6 hourly intervals for 7 475 
days follow-up, after treatment with each i.v. artesunate dosing regimen, were 476 
simulated. The 100 hypothetical datasets were generated from the last 100 of the 4000 477 
draws of ϕ and Ω  as defined in [1]. For each patient population 100 vectors of ϕi 478 
were then sampled from this distribution at each of the 100 draws of ϕand ΩThe 479 
inverse logistic transform (a × (1 − logit−1(ϕi))) + b × logit
−1(ϕi) , where 480 
logit−1(x) = 1/(1 + e−x) and a and b are the lower and upper bounds, respectively, 481 
for the PD parameters in Table 4 and Table S1) was then applied to each of the ϕi 482 
vectors, to obtain individual-specific PD parameters on the original scale and within 483 
their biologically plausible bounds. These vectors were then used to simulate 484 
parasitaemia profiles from the within-host PK-PD model for each hypothetical patient 485 
(Figure S5).  486 
 487 
For each dosing regimen examined, the simulated DHA concentration profiles (Figure 488 
S4) do not vary between datasets. The individual-specific PD parameters for the 489 
hypothetical patients vary between datasets, but not between dosing regimens. Details 490 
concerning the calculation of PC24≥99% for hypothetical patients are provided in the 491 
Supplementary Text 5. The simulation of parasitaemia profiles for infections with 492 
 on M






















reduced ring stage sensitivity to artemisinin derivatives required shortening the DHA 493 
killing window from 6-44 hours, where the drug is known to have an effect, to 12-44 494 
hours in supplementary equation [S5]. The process outlined above is then repeated for 495 
the within-host PK-PD model with shortened DHA killing window.  496 
 497 
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 674 
FIGURE LEGENDS 675 
Figure 1. Posterior predictive check of the within-host PK-PD model fitted to the 676 
observed data (n = 94 patients). In the upper panel of (a), the solid black circles are 677 
the observed log10 parasitaemia (parasites / l of blood), and the following are plotted 678 
for bins across the independent variable, time after i.v. artesunate administration: 679 
median (middle red dashed line), 5th and 95th percentiles (lower and upper red 680 
dashed lines, respectively) of the observed parasitaemia; and 95% credible intervals 681 
for the median (red region), 5th and 95th percentiles (blue regions) predicted from the 682 
within-host PK-PD model. Dashed horizontal line is the microscopic limit of 683 
detection (LOD) of 50 parasites / l of blood. In the lower panel of (a), the solid black 684 
line is the observed fraction of parasite counts at each sampling time below the LOD, 685 
and the blue region is the 95% credible interval for the median fraction of below LOD 686 
parasitaemia samples predicted from the within-host PK-PD model with noise added. 687 
In (b), are the medians (black dot) and 95% credible intervals (error bars) for the 688 
percentage of children and adults that cleared 99% of their admission parasitaemia by 689 
24 hours (PC24≥99%) derived from 4000 replicated datasets simulated from the 690 
within-host PK-PD model. The observed PC24≥99% derived from the 94 patients was 691 
82% for children and 70% for adults and these are indicated by the black dashed lines. 692 
 on M






















The grey shaded regions are corresponding 95% confidence intervals: (70%-90%) for 693 
children and (35%-93%) for adults. 694 
 695 
Figure 2. Comparison of the median (black dot) and 95% credible interval (error 696 
bars) for the PC24≥99% achieved by hypothetical adults, larger (≥20 kg) and smaller 697 
(<20 kg) children. PC24≥99% calculated from 100 datasets consisting of simulated 698 
parasitaemia profiles for 100 adults, 100 larger children and 100 smaller children, 699 
with either artemisinin sensitive (top) or reduced ring stage sensitivity to artemisinin  700 
(bottom row is DHA killing window shortened from 6-44 hours to 12-44 hours) 701 
infections, administered the standard (2.4 mg/kg of i.v. artesunate at 0, 12, and 24, 48 702 
and 72 hours), revised (3 mg/kg of i.v. artesunate for smaller children (<20 kg) and 703 
2.4 mg/kg for adults and larger children (>20 kg) at 0, 12, and 24, 48 and 72 hours) 704 
and simplified (4 mg/kg of i.v. artesunate at 0, 24 and 48 hours) dosing regimens. The 705 
black and purple dashed lines are the percentage PC24≥99% for the conventional 5-706 
dose regimen of 2.4 mg/kg i.v. artesunate (standard regimen) and simplified 3-dose 707 
regimen of 4 mg/kg i.v. artesunate (simplified regimen) reported in Kremsner et al. 708 
2012
 
(10) (85% and 78%, respectively) and the black and purple regions are the 709 
corresponding 95% confidence intervals (77%–93%) and (69%–87%), respectively. 710 
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Table 1. Study site, population, design, dosing scheme and parasitaemia sampling times for 
each study. 
Research Team Kremsner et al. 2012 (10) Maude et al. 2009 (13) 
Site  Gabon, Malawi Bangladesh 
Population Children with severe malaria Adults with severe malaria 
Design Randomised Controlled Trial Clinical Study 




II – 4 mg/kg IV at 0, 24, 48 h 
2.4 mg/kg i.v. at 0, 12, 24 and 




2 samples/patient taken from times
b
 
0.083, 0.167, 0.25, 0.5, 1, 2, 4, and 
6 h 
0, 0.167, 0.5, 1, 2, and 4 h 
Parasitaemia 0, 6, 12, 18, 24 h and then every 6 h 




0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 
24 h and then every 6 h until 
parasite clearance 
a
Only these patients included in the analysis 
b
Patients randomly allocated to one of eight different sampling groups where each sampling 
group has two time points (e.g. group 1–5 min, 2 h post first dose). 
c
Negative slide defined as number of circulating parasitized blood cells below the limit of 
























Table 2.  Summary of the number of blood samples for parasitaemia measurement, including 
the number of samples below the microscopic limit of detection (LOD), and baseline patient 
characteristics for each study. 











Median samples per patient [range] 
463  
68  
6 [2, 9] 
87  
5  
11 [1, 14] 
Baseline patient characteristics
b
   
Median Parasitaemia  
(parasites / l of blood) 
214,824  
[869 to 1,870,264] 
92,630 
[22,608 to 534,554] 
Age (years)  
 
3 [0.6 to 9.3] 37.5 [22 to 62] 
Weight (kg) 
 
12 [6 to 24] 60 [33 to 75] 
a
LOD – Limit of detection for microscopic blood film examination: 50 parasites / l of blood 
b



















































Table 3. Parameter definitions for the within-host pharmacokinetic-pharmacodynamic model. 
Parameter Description IPL Initial parasite load of patient on admission 𝜇𝐼𝑃𝐿∗  Mean of the age distribution of the initial parasite load (hours) before truncation 
(normal). μIPL Mean of the age distribution of the initial parasite load (hours) after truncation 
(truncated normal).  𝜎𝐼𝑃𝐿∗  Standard deviation of the age distribution of the initial parasite load (hours) 
before truncation (normal). σIPL Standard deviation of the age distribution of the initial parasite load (hours) after 
truncation (truncated normal).  PMF Parasite multiplication factor. Number of parasites released by a ruptured 
schizont at the end of the lifecycle.  kmax Maximal killing rate of the drug (/ hour) EC50 In vivo concentration when killing rate is 50% of kmax (ng/ml)  γ Slope of in vivo concentration-effect curve  ke0 Rate the drug moves from the central compartment (blood plasma) to a 
hypothetical effect-site (intraerythrocytic compartment) (/ hour) δ𝑃 Rate of parasite removal due to processes other than drug (/ hour). Patients are 



























Table 4. Posterior summaries for the population mean pharmacodynamics (PD) parameters, 
between subject variability (BSV) and study-specific residual errors calculated from 4000 
draws from the posterior distribution. 
Parameter Bounds
a
 Posterior median 




Population average PD parameter
d







𝜇𝐼𝑃𝐿∗ (hr) (1,48) 5.41  
(2.49, 11.39) 
689 1 
μIPL(hr)  12.95  
(11.53, 15.90) 
  
𝜎𝐼𝑃𝐿∗ (hr) (4,14) 12.74  
(11.75, 13.46) 
1839 1 
σIPL(hr)  8.47  
(7.73, 9.51) 
  
PMF (5,20) 11.39  
(6.47, 17.75) 
2379 1 
kmax(hr−1) (0.26,1) 0.53  
(0.47, 0.6) 
342 1.01 
EC50(ng/ml) (1.44,533) 20.35  
(7.97, 41.26) 
756 1.01 
γ (1,13) 7.14  
(2.74, 11.51) 
2893 1 
ke0 (hr−1) (0.01,10) 0.21  728 1 
 on M




















(0.11, 0.33) δ𝑝 (hr−1) (0.001,0.1) 0.06  
(0.02, 0.09) 
744 1 
Between subject variability (ω)e ωIPL  1.51  
(1.23, 1.86) 1475 1 ωμIPL  0.37  
(0.02, 1.01) 1022 1 ωσIPL  1.76  
(1.02, 2.78) 306 1.01 ωPMF  0.63  
(0.03, 2.14) 2468 1 ωkmin  1.09  
(0.81, 1.45) 675 1.01 ωEC50  0.58  
(0.04, 1.25) 717 1 ωγ  0.63  
(0.03, 2.13) 3498 1 ωke0  0.4  
(0.04, 1.01) 392 1.01 ωkmin  0.42  
(0.02, 1.81) 469 1 
Study-specific residual error (σ) σ1  0.95  
(0.86, 1.05) 1439 1 
 on M




















σ2  0.69  
(0.56, 0.89) 745 1.01 
a
A justification for the bounds is provided in supplementary Table S1. 
b
Effective sample size (ESS) is the number of independent draws of the parameter of interest 
from the posterior distribution (see METHODS). 
c
If all chains have converged to a common distribution ?̂? will be one, otherwise it will be 
greater than one (see METHODS). 
d
Prior to drug administration the initial parasite load (𝐼𝑃𝐿) of each patient is distributed 
among the 48 hourly age intervals of the P. falciparum lifecycle according to a truncated 
normal distribution with location parameter μ𝐼𝑃𝐿∗  hours, scale parameter σ𝐼𝑃𝐿∗  hours and 
truncation limits 1 to 48 hours (Supplementary Text 1 equation [S1]). 𝜇𝐼𝑃𝐿 and 𝜎𝐼𝑃𝐿 are the 
mean and standard deviation of the truncated parasite age distribution. Definitions for the 
nine model parameters are provided in Table 3. 
e
Between subject variability (BSV) is the population standard deviation of the individual PD 
parameters on the logistic transform scale (see METHODS equation [1]). BSV was only 
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